News
The information below is intended for the healthcare media.
20/6/2025
pharma&’s ATHENA-MONO Clinical Trial Data Suggests That Rubraca® is a Potential Beneficial Therapeutic Option for Patients with HRD-Negative and HRD-Positive Tumors
5/6/2025
pharma& to Highlight Efficacy and Safety Data for Rucaparib in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
3/6/2025
pharma& Receives Swissmedic Approval for Pegasys® Manufacturing Site Variation, Including Loba biotech for API Production and Ensuring a Stable Long-term Supply in Switzerland
28/5/2025
pharma& Receives MHRA Approval for Pegasys® Manufacturing Site Variation, Adding Loba biotech for API Production and Ensuring a Reliable, Long-term Supply in the UK
21/5/2025
pharma& Announces Review Classification for supplemental New Drug Application (sNDA) Accepted by U.S. FDA for Rubraca® (rucaparib) Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
29/4/2025
pharma& Receives EMA Approval for Pegasys® Manufacturing Site Variation, Adding Loba biotech for API Production and Securing a Stable, Long-term Supply
10/4/2025
pharma& Announces Rubraca® (rucaparib) Global Success and Expansion Q1 2025 Update
21/2/2025
Rubraca® (rucaparib) is Recommended by NICE as a First-Line Maintenance Treatment for Eligible Women with BRCA-Mutation Negative Advanced Ovarian Cancer
17/2/2025
Rubraca® (rucaparib) is Now Reimbursed in Italy as a First-Line Maintenance Treatment for all Eligible Women with Advanced Ovarian Cancer
6/2/2025
pharma& to Highlight Long-Term Data for Rubraca® (rucaparib) in Advanced Ovarian Cancer at 2025 ESGO Annual Congress
7/11/2024
Rubraca® (rucaparib) is now Reimbursed in Spain as a First-Line Maintenance Treatment for all Eligible Women with Advanced Ovarian Cancer
16/10/2024
Rubraca® (rucaparib) is now Reimbursed in France as a First-Line Maintenance Treatment for all Eligible Women with Advanced Ovarian Cancer
24/9/2024
The pharma& Group Enters Into an Exclusive Promotional Agreement with Tolmar, Inc. to Promote Rubraca® (rucaparib) in the U.S. for the Treatment of Metastatic Castration-Resistant Prostate Cancer
14/8/2024
European Commission Approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a Treatment for all Eligible Patients With the Myeloproliferative Neoplasms (MPNs) Blood Cancers Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
1/7/2024
pharmaand GmbH Receives Positive CHMP Opinion for Pegasys® as a Treatment for all Eligible Patients with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
31/5/2024
pharma& Updates on the Phase 3 ATHENA-COMBO Trial Evaluating Rucaparib (Rubraca®) in Combination with Nivolumab in First-Line Maintenance Treatment in Women With Advanced Ovarian Cancer
30/4/2024
pharma& Joins the United Nations Global Compact
16/3/2024
pharma&’s Rubraca® (rucaparib) ATHENA-MONO Clinical Trial Data in First-Line Maintenance Treatment Suggest Benefit Continues Beyond Completion of Treatment and First Progression
1/2/2024
pharmaand GmbH’s Rubraca®▼ (rucaparib) Approved in the United Kingdom as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
1/2/2024
pharmaand GmbH and GHN Pharma Nordic AB Announce Collaboration Extension and Expansion
17/1/2024
pharma& Acquires the Global Rights to satraplatin from Dayton Therapeutics
20/11/2023
European Commission Approves pharmaand GmbH’s Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
16/10/2023
pharmaand GmbH Receives Positive CHMP Opinion for Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
Read more in our News Archive